PE20040120A1 - Derivados de quinolina como antagonistas de npy - Google Patents
Derivados de quinolina como antagonistas de npyInfo
- Publication number
- PE20040120A1 PE20040120A1 PE2003000111A PE2003000111A PE20040120A1 PE 20040120 A1 PE20040120 A1 PE 20040120A1 PE 2003000111 A PE2003000111 A PE 2003000111A PE 2003000111 A PE2003000111 A PE 2003000111A PE 20040120 A1 PE20040120 A1 PE 20040120A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ring
- quinolin
- pyrrolidin
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02001967 | 2002-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040120A1 true PE20040120A1 (es) | 2004-03-06 |
Family
ID=27635782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000111A PE20040120A1 (es) | 2002-02-04 | 2003-01-31 | Derivados de quinolina como antagonistas de npy |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6696467B2 (enExample) |
| EP (1) | EP1474145B1 (enExample) |
| JP (1) | JP4216196B2 (enExample) |
| KR (1) | KR100659428B1 (enExample) |
| CN (1) | CN100383124C (enExample) |
| AR (1) | AR038249A1 (enExample) |
| AT (1) | ATE392897T1 (enExample) |
| AU (1) | AU2003205679B2 (enExample) |
| BR (1) | BR0307441A (enExample) |
| CA (1) | CA2473181A1 (enExample) |
| DE (1) | DE60320529T2 (enExample) |
| ES (1) | ES2304498T3 (enExample) |
| MX (1) | MXPA04007502A (enExample) |
| PE (1) | PE20040120A1 (enExample) |
| PL (1) | PL372295A1 (enExample) |
| RU (1) | RU2298002C2 (enExample) |
| TW (1) | TW200400032A (enExample) |
| UY (1) | UY27646A1 (enExample) |
| WO (1) | WO2003066055A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| JP2004110367A (ja) * | 2002-09-18 | 2004-04-08 | Hitachi Ltd | 記憶装置システムの制御方法、記憶制御装置、および記憶装置システム |
| WO2005030754A1 (en) * | 2003-09-24 | 2005-04-07 | Janssen Pharmaceutica, N.V. | Indole or quinoline derivatives as non-pepticid npy y2 receptor inhibitors useful for the treatment of anxiolytic and depressive disorders and obesity |
| JP4768628B2 (ja) | 2003-11-19 | 2011-09-07 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの二環系阻害剤及びその使用方法 |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| AU2006299671A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| RU2314295C2 (ru) * | 2006-03-01 | 2008-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | 2-гетарилзамещенные 1,3-трополона, способ их получения (варианты) и фармацевтическая композиция антимикробного действия |
| WO2008141077A1 (en) * | 2007-05-10 | 2008-11-20 | Janssen Pharmaceutica N.V. | Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives |
| EP2182950B8 (en) * | 2007-05-17 | 2017-08-23 | Helperby Therapeutics Limited | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
| WO2010056865A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
| AR077292A1 (es) * | 2009-06-29 | 2011-08-17 | Agios Pharmaceuticals Inc | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas |
| US20120142944A1 (en) * | 2010-12-03 | 2012-06-07 | Dow Agrosciences Llc | Processes for the preparation of enamines |
| EP2675787B1 (en) | 2011-02-18 | 2018-03-28 | Endo Pharmaceuticals Inc. | Aminoindane compounds and use thereof in treating pain |
| CA2839703A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| PE20140868A1 (es) | 2011-06-24 | 2014-07-18 | Amgen Inc | Antagonistas trpm8 y su uso en tratamientos |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| RS59007B1 (sr) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihidropirolopiridinski inhibitori ror-gama |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| KR20180086221A (ko) * | 2015-11-20 | 2018-07-30 | 비타이 파마슈티컬즈, 인코포레이티드 | Ror-감마의 조절물질 |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| RS63776B1 (sr) * | 2016-07-14 | 2022-12-30 | Crinetics Pharmaceuticals Inc | Modulatori somatostatina i njihove upotrebe |
| TWI774767B (zh) * | 2017-05-12 | 2022-08-21 | 瑞士商多蒂孔股份有限公司 | 茚烷衍生物及其在有機電子產品的用途 |
| MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| CA3073051A1 (en) * | 2017-08-17 | 2019-02-21 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| ES2923529T3 (es) | 2018-01-17 | 2022-09-28 | Crinetics Pharmaceuticals Inc | Proceso para fabricar moduladores de somatostatina |
| RU2702648C1 (ru) * | 2019-07-11 | 2019-10-09 | федеральное государственное автономное образовательное учреждение высшего образования «Южный федеральный университет» | 5,7-Ди(трет-бутил)-2-(4,7-дихлор-8-метил-5-нитрохинолин-2-ил)-4-нитро-1,3-трополон, обладающий цитотоксической активностью |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| CA2133620A1 (en) * | 1993-10-28 | 1995-04-29 | Werner Hofheinz | Aminoquinoline derivatives |
| RU2161967C2 (ru) * | 1994-08-18 | 2001-01-20 | Дзе Проктер Энд Гэмбл Компани | Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора |
| US5552411A (en) * | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| EP1105123B1 (en) | 1998-08-14 | 2004-04-07 | F.Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| PT1105122E (pt) | 1998-08-14 | 2005-08-31 | Hoffmann La Roche | Composicoes farmaceuticas que contem inibidores de lipase |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| DE10064105A1 (de) * | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| DE60225274T2 (de) * | 2001-05-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Chinolinderivate als liganden für den neuropeptid-y-rezeptor |
-
2003
- 2003-01-27 ES ES03702533T patent/ES2304498T3/es not_active Expired - Lifetime
- 2003-01-27 AU AU2003205679A patent/AU2003205679B2/en not_active Ceased
- 2003-01-27 JP JP2003565479A patent/JP4216196B2/ja not_active Expired - Fee Related
- 2003-01-27 CN CNB038032805A patent/CN100383124C/zh not_active Expired - Fee Related
- 2003-01-27 RU RU2004126936/04A patent/RU2298002C2/ru not_active IP Right Cessation
- 2003-01-27 MX MXPA04007502A patent/MXPA04007502A/es active IP Right Grant
- 2003-01-27 BR BR0307441-2A patent/BR0307441A/pt not_active IP Right Cessation
- 2003-01-27 AT AT03702533T patent/ATE392897T1/de not_active IP Right Cessation
- 2003-01-27 PL PL03372295A patent/PL372295A1/xx not_active Application Discontinuation
- 2003-01-27 KR KR1020047012036A patent/KR100659428B1/ko not_active Expired - Fee Related
- 2003-01-27 CA CA002473181A patent/CA2473181A1/en not_active Abandoned
- 2003-01-27 WO PCT/EP2003/000777 patent/WO2003066055A1/en not_active Ceased
- 2003-01-27 DE DE60320529T patent/DE60320529T2/de not_active Expired - Fee Related
- 2003-01-27 EP EP03702533A patent/EP1474145B1/en not_active Expired - Lifetime
- 2003-01-30 TW TW092102218A patent/TW200400032A/zh unknown
- 2003-01-31 PE PE2003000111A patent/PE20040120A1/es not_active Application Discontinuation
- 2003-01-31 AR ARP030100304A patent/AR038249A1/es not_active Application Discontinuation
- 2003-02-03 UY UY27646A patent/UY27646A1/es not_active Application Discontinuation
- 2003-02-04 US US10/358,006 patent/US6696467B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003066055A1 (en) | 2003-08-14 |
| CN1627945A (zh) | 2005-06-15 |
| UY27646A1 (es) | 2003-08-29 |
| US6696467B2 (en) | 2004-02-24 |
| AR038249A1 (es) | 2005-01-05 |
| CA2473181A1 (en) | 2003-08-14 |
| US20030153553A1 (en) | 2003-08-14 |
| JP2005523901A (ja) | 2005-08-11 |
| PL372295A1 (en) | 2005-07-11 |
| JP4216196B2 (ja) | 2009-01-28 |
| ES2304498T3 (es) | 2008-10-16 |
| AU2003205679B2 (en) | 2006-06-29 |
| ATE392897T1 (de) | 2008-05-15 |
| TW200400032A (en) | 2004-01-01 |
| MXPA04007502A (es) | 2004-11-10 |
| DE60320529D1 (de) | 2008-06-05 |
| RU2298002C2 (ru) | 2007-04-27 |
| EP1474145B1 (en) | 2008-04-23 |
| RU2004126936A (ru) | 2005-10-10 |
| KR100659428B1 (ko) | 2006-12-19 |
| AU2003205679A1 (en) | 2003-09-02 |
| CN100383124C (zh) | 2008-04-23 |
| EP1474145A1 (en) | 2004-11-10 |
| BR0307441A (pt) | 2005-01-04 |
| DE60320529T2 (de) | 2009-06-10 |
| KR20040081484A (ko) | 2004-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20040120A1 (es) | Derivados de quinolina como antagonistas de npy | |
| PE20080075A1 (es) | Compuestos fenil amido heterociclicos condensados | |
| NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
| CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
| PE20041016A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| PE20050465A1 (es) | Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
| PE20040780A1 (es) | Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion | |
| PE20060627A1 (es) | Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 | |
| PE20080186A1 (es) | Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2 | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| PE20010685A1 (es) | Composicion que comprende un polipeptido antagonista del receptor de interleuquina 1 y una diarilsulfonilurea como inhibidor del procesamiento y la liberacion de il-1 | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| PE20060736A1 (es) | DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2 | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
| ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
| PE20080211A1 (es) | Compuestos derivados de 6-(bencilo sustituido con heterociclilo)-4-oxoquinolina como inhibidores de integrasa del vih | |
| PE20050079A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |